Video

Trials evaluating IL-6 inhibitors such as sarilumab in RA patients have used global function and disability as outcome benchmarks for assessing patient outcomes? Why is this important?

Name: Trials evaluating IL-6 inhibitors such as sarilumab in RA patients have used global function and disability as outcome benchmarks for assessing patient outcomes? Why is this important?
Uploaded: 2017-02-27T00:00:00+00:00
Description: Trials evaluating IL-6 inhibitors such as sarilumab in RA patients have used global function and disability as outcome benchmarks for assessing patient outcomes? What are the findings and why is this important?

Published: February 27, 2017

Trials evaluating IL-6 inhibitors such as sarilumab in RA patients have used global function and disability as outcome benchmarks for assessing patient outcomes? Why is this important?

Trials evaluating IL-6 inhibitors such as sarilumab in RA patients have used global function and disability as outcome benchmarks for assessing patient outcomes? What are the findings and why is this important?

Overview

CLICK HERE FOR CME CREDIT

Created by

Presenter

William Shergy, MD

Associate Clinical Professor of Medicine
University of Alabama at Birmingham
School of Medicine
Huntsville, Alabama
Assistant Consulting Professor of Medicine
Duke University Medical Center
Durham, North Carolina